Bavarian Nordic-sponsored study has commenced dosing Study marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in solid tumors COPENHAGEN, Denmark, September 18, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer immunotherapy, CV301, and Roches`s checkpoint inhibitor, atezolizumab (TECENTRIQ®), for the treatment of patients with locally advanced or metastatic urothelial bladder cancer. Bavarian Nordic`s CV301 targets tumor-associated antigens, CEA and MUC1, which are overexpressed on multiple solid tumors, including bladder...
|
